Genomic Landscape Comparison of Cardiac versus Extra-Cardiac Angiosarcomas

Angiosarcomas (ASs) are rare malignant vascular entities that can affect several regions in our body, including the heart. Cardiac ASs comprise 25-40% of cardiac sarcomas and can cause death within months of diagnosis. Thus, our aim was to identify potential differences and/or similarities between c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicines 2023-12, Vol.11 (12), p.3290
Hauptverfasser: Gozzellino, Livia, Nannini, Margherita, Urbini, Milena, Pizzi, Carmine, Leone, Ornella, Corti, Barbara, Baldovini, Chiara, Angeli, Francesco, Foà, Alberto, Pacini, Davide, Folesani, Gianluca, Costa, Alice, Palumbo, Teresa, Nigro, Maria Concetta, Pasquinelli, Gianandrea, Astolfi, Annalisa, Pantaleo, Maria Abbondanza
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Angiosarcomas (ASs) are rare malignant vascular entities that can affect several regions in our body, including the heart. Cardiac ASs comprise 25-40% of cardiac sarcomas and can cause death within months of diagnosis. Thus, our aim was to identify potential differences and/or similarities between cardiac and extra-cardiac ASs to enhance targeted therapies and, consequently, patients' prognosis. Whole-transcriptome analysis of three cardiac and eleven extra-cardiac non-cutaneous samples was performed to investigate differential gene expression and mutational events between the two groups. The gene signature of cardiac and extra-cardiac non-cutaneous ASs was also compared to that of cutaneous angiosarcomas (n = 9). and alterations were more recurrent in extra-cardiac ASs, while -gene family overexpression was peculiar to cardiac ASs. Additionally, in vitro functional analyses showed that upregulation conferred a growth advantage to recipient cells, partly supporting the cardiac AS aggressive phenotype and patients' scarce survival rate. These features should be considered when investigating alternative treatments.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines11123290